Analysts maintain a bullish outlook on AbbVie, with comprehensive analysis available through InvestingPro's detailed research reports, which provide deeper insights into the company's growth prospects ...

“Following the results of these trials, AbbVie began an evaluation of the emraclidine intangible asset for impairment which resulted in a significant decrease in the estimated future cash flows for ...

AbbVie ABBV underwent analysis ... and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products ...

IRVINE, Calif., Jan. 7, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its third annual CoolMonth featuring CoolSculpting® Elite. The celebration is an ...

Truist analyst Srikripa Devarakonda lowered the firm’s price target on AbbVie (ABBV ... being more pro-pharma than expected. For the company, the firm is positive on its longer-term outlook ...

She is the co-founder of PowerZone Trading, a company that has provided programming, consulting, and strategy development services to active traders and investors since 2004. Diane Costagliola is ...

IRVINE, Calif., Jan. 7, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its third annual CoolMonth featuring CoolSculpting® Elite. The celebration is an ...

In a regulatory filing, AbbVie (ABBV) stated, “Reported GAAP earnings and adjusted non-GAAP earnings for the fourth quarter of 2024 are expected to include acquired IPR&D and milestones expense ...